Aelix Therapeutics raises $12.7 mln

Aelix Therapeutics said Monday that it completed a Series A funding round of €11.5 M ($12.7 million) led by Ysios Capital. A syndicate of new investors including Johnson & Johnson Innovation – JJDC Inc. and Caixa Capital Risc also invested. Aelix is a drug development company specialized in the discovery and development of immunotherapies against HIV infection.

North AmericaUSBriefs